MORRISTOWN, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a...
Company Enters Growth Phase in Hospital Market with Support of Deerfield Acquisition to Augment Company’s Core...
MORRISTOWN, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (the “Company” or “Melinta”...
Bids due on March 2, 2020 by 4:00 p.m. Eastern Time Company Previously Announced Agreement of its Secured...
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...
MORRISTOWN, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company”...
MORRISTOWN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...
~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~ ~ Company...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.